Clariane


Integrating the above-expectation mid-term guidance

06/06/24 -"We have incorporated the latest financial guidance, which was largely above our previous forecasts, resulting in a significant boost to our target price. Please note that the significant imbalance ..."

Pages
66
Language
English
Published on
06/06/24
You may also be interested by these reports :
26/07/24
No major surprises in H1 FY24 – sales and adjusted EBIT were in-line with consensus, but net income was ~2% lower. At CER, Q2 revenue grew 5.2%yoy, ...

26/07/24
Dräger reported Q2 24 figures bang in line with its preliminary figures. Revenue was up 2%, as the strength in safety was accompanied by some ...

25/07/24
Sartorius Stedim reported a decent set of Q2 figures, meeting estimates. However, the stock has lost over 7% since the announcement, as investors ...

25/07/24
Sartorius reported a decent set of Q2 figures, beating estimates. However, the stock has lost over 8% since the announcement, as investors were ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO